Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Photo activation of HPPH encapsulated in “Pocket” liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts

Authors Sine J, Urban C, Thayer D, Charron H, Valim N, Tata DB, Schiff R, Blumenthal R, Joshi A, Puri A

Received 2 August 2014

Accepted for publication 11 October 2014

Published 19 December 2014 Volume 2015:10(1) Pages 125—145

DOI https://doi.org/10.2147/IJN.S72143

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Thomas J Webster

Jessica Sine,1,* Cordula Urban,2,* Derek Thayer,1 Heather Charron,2 Niksa Valim,2 Darrell B Tata,3 Rachel Schiff,4 Robert Blumenthal,1 Amit Joshi,2 Anu Puri1

1Membrane Structure and Function Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute – Frederick, Frederick, MD, USA; 2Department of Radiology, Baylor College of Medicine, Houston, TX, USA; 3US Food and Drug Administration, CDRH/OSEL/Division of Physics, White Oak Campus, MD, USA; 4Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA

*These authors contributed equally to this work

Abstract: We recently reported laser-triggered release of photosensitive compounds from liposomes containing dipalmitoylphosphatidylcholine (DPPC) and 1,2 bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC). We hypothesized that the permeation of photoactivated compounds occurs through domains of enhanced fluidity in the liposome membrane and have thus called them “Pocket” liposomes. In this study we have encapsulated the red light activatable anticancer photodynamic therapy drug 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) (Ex/Em410/670 nm) together with calcein (Ex/Em490/517 nm) as a marker for drug release in Pocket liposomes. A mole ratio of 7.6:1 lipid:HPPH was found to be optimal, with >80% of HPPH being included in the liposomes. Exposure of liposomes with a cw-diode 660 nm laser (90 mW, 0–5 minutes) resulted in calcein release only when HPPH was included in the liposomes. Further analysis of the quenching ratios of liposome-entrapped calcein in the laser treated samples indicated that the laser-triggered release occurred via the graded mechanism. In vitro studies with MDA-MB-231-LM2 breast cancer cell line showed significant cell killing upon treatment of cell-liposome suspensions with the laser. To assess in vivo efficacy, we implanted MDA-MB-231-LM2 cells containing the luciferase gene along the mammary fat pads on the ribcage of mice. For biodistribution experiments, trace amounts of a near infrared lipid probe DiR (Ex/Em745/840 nm) were included in the liposomes. Liposomes were injected intravenously and laser treatments (90 mW, 0.9 cm diameter, for an exposure duration ranging from 5–8 minutes) were done 4 hours postinjection (only one tumor per mouse was treated, keeping the second flank tumor as control). Calcein release occurred as indicated by an increase in calcein fluorescence from laser treated tumors only. The animals were observed for up to 15 days postinjection and tumor volume and luciferase expression was measured. A significant decrease in luciferase expression and reduction in tumor volume was observed only in laser treated animal groups injected with liposomes containing HPPH. Histopathological examination of tumor tissues indicated tumor necrosis resulting from laser treatment of the HPPH-encapsulated liposomes that were taken up into the tumor area.

Keywords: laser-triggered payload release, photo-agents, photopolymerizable phospholipids, tumor regression, phototriggering

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Readers of this article also read:

Predicting frequent COPD exacerbations using primary care data

Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2439-2450

Published Date: 9 November 2015

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

Therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer

Su H, Luo Q, Xie H, Huang XF, Ni YH, Mou YB, Hu QG

International Journal of Nanomedicine 2015, 10:1921-1930

Published Date: 10 March 2015

Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles

Qiu L, Hu B, Chen H, Li S, Hu Y, Zheng Y, Wu X

International Journal of Nanomedicine 2015, 10:1415-1423

Published Date: 17 February 2015

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes [Erratum]

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA

International Journal of Nanomedicine 2015, 10:595-596

Published Date: 14 January 2015

Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes [Corrigendum]

Perez AP, Casasco A, Schilrreff P, Defain Tesoriero MV, Duempelmann L, Pappalardo JS, Altube MJ, Higa L, Morilla MJ, Petray P, Romero EL

International Journal of Nanomedicine 2015, 10:169-170

Published Date: 29 December 2014

Covalent IR820-PEG-diamine nanoconjugates for theranostic applications in cancer

Fernandez-Fernandez A, Manchanda R, Carvajal DA, Lei T, Srinivasan S, McGoron AJ

International Journal of Nanomedicine 2014, 9:4631-4648

Published Date: 6 October 2014

Nanopharmaceuticals (part 1): products on the market

Weissig V, Pettinger TK, Murdock N

International Journal of Nanomedicine 2014, 9:4357-4373

Published Date: 15 September 2014

Topiramate in the prevention of migraine: a review of its efficacy, tolerability, and acceptability

Domenico D’Amico, Licia Grazzi, Gennaro Bussone

Neuropsychiatric Disease and Treatment 2006, 2:261-267

Published Date: 15 September 2006